28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Over six months, the intervention group showed a stable global cognitive function score (Mini Mental Status Examination), whereas the control group showed a cognitive decline (ANCOVA-interaction: F1, 14 = 5.083, p = .041; controlled for disease duration and education). 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Our sample had a mean age of 66.8 (SD = 5.3) years, a mean HAM-D score of 19.4 (SD = 7.5), and a mean PHQ-9 score of 18.0 (SD = 6.3). 5 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source
Thinning of retinal layers, measured using optical coherence tomography (OCT), is associated with some neurodegenerative disorders such as established Alzheimer's disease and multiple sclerosis. 5 key findings →
Design: systematic review Participants: 622 Evidence: high
Full summary, score breakdown and related studies → Original source
The overall number of participants enrolled was 192, with a mean (standard deviation) amyloid PET load at baseline of 101.80 (29.80) centiloids. 5 key findings →
Design: clinical trial Participants: 149 Evidence: low
Full summary, score breakdown and related studies → Original source
Each matched cohort included 23,386 (semaglutide vs sitagliptin), 22,584 (vs empagliflozin), and 19,206 (vs glipizide) patients. 5 key findings →
Design: cohort study Participants: 23,386 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. 3 key findings →
Design: systematic review Participants: 19 Evidence: high
Full summary, score breakdown and related studies → Original source
The sample was mostly female (65%), White (76%), and 74 years old on average. 5 key findings →
Design: retrospective cohort Participants: 342,608 Evidence: moderate
Full summary, score breakdown and related studies → Original source
AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. 5 key findings →
Design: open-label trial Participants: 63 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of seven studies were included. The forest plot results showed that taking lithium therapy reduced the risk of AD (RR 0.59, 95% confidence interval [CI]: 0.44-0.78) and is also protective in reducing the risk of dementia (RR 0.66, 95% CI: 0.56-0.77). 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
A growing number of investigations are exploring the utility of intranasal insulin as a means of mitigating cognitive decline. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Patients treated with galantamine 24 mg/day had a significantly better outcome than placebo on ADAS-cog; the treatment difference was 3 points on the intention-to-treat (ITT) analysis ( p = 0.01) and 4.2 points on per protocol analysis ( p = 0.001). 4 key findings →
Participants: 285 Evidence: high
Full summary, score breakdown and related studies → Original source
111,485 articles were initially retrieved; 288 full articles were reviewed and 89.6% subsequently deemed ineligible due to exclusion of participants with co-existence of dementia and Parkinsonism. 5 key findings →
Design: randomized controlled trial Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source
Sleep disorders, particularly insomnia and obstructive sleep apnea, are increasingly implicated as significant contributors to cognitive decline, dementia, and neurodegenerative diseases such as Alzheimer's disease (AD) and vascular cognitive impairment and dementia (VCID). 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
A relationship between sleep disorders and cognitive dysfunctions was reported in Parkinson's Disease (PD), however, some studies did not confirm the link. 4 key findings →
Design: meta-analysis Participants: 54 Evidence: high
Full summary, score breakdown and related studies → Original source
The cohort study revealed that persistent HI significantly increased the risk of heart disease (P < 0.001, HR 1.63, 95% CI 1.31-2.03), stroke (P 0.004, HR 1.59, 95% CI 1.16-2.18), chronic lung disease (P 0.002, HR 1.53, 95% CI 1.17-1.99), and emotional, nervous, or psychiatric problems (P 0.016, HR 2.03, 95% CI 1.14-3.60). 5 key findings →
Design: cohort study Participants: 504,307 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Subjects experiencing multisensory impairments concurrent with visual impairment demonstrated a negative association with cognitive function. 5 key findings →
Design: cohort study Participants: 500,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 2 184 847 Danish citizens aged between 65 and 95 years, there were 3024 individuals with DLB (mean [SD] age, 78 [6], 1894 [62.6%] male) and 3808 with PDD (mean [SD] age, 78 [6], 2400 [63.0%] male) who were matched with 30 240 and 38 080 controls, respectively. 5 key findings →
Design: case-control study Participants: 3,024 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Increased absolute sugar intake (g/day) was significantly associated with a higher risk of all-cause dementia (HR = 1.003, [95%CI: 1.002-1.004], p < 0.001) and Alzheimer's disease (1.002, [1.001-1.004], 0.005). 5 key findings →
Design: cohort study Participants: 210,832 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The results show that the western diet pattern is a risk factor for developing AD. 5 key findings →
Design: systematic review Participants: 38 Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is projected to become the highest-burden neurological disorder globally. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Of 65 participants with biomarker-confirmed AD, 21 (32.3%) were αS-SAA positive. 4 key findings →
Design: longitudinal study Participants: 108 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Thirty-six resident videos were shared with family (N = 50) and staff (N = 38) during care plan meetings. 5 key findings →
Participants: 50 Evidence: high
Full summary, score breakdown and related studies → Original source
This large review pooled 113 studies (nearly 30,000 people) comparing different forms of blood phosphorylated tau for detecting Alzheimer's pathology. p-tau217 was clearly the best-performing marker, correctly identifying disease pathology about 88% of the time, outperforming other tau variants like p-tau181. 4 key findings →
Design: meta-analysis Participants: 29,625 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This randomized trial followed 2,111 older adults at risk for cognitive decline across 5 US sites for two years, comparing a highly structured lifestyle program (regular exercise, MIND diet, cognitive/social engagement, health coaching) against a lower-intensity, self-guided version of the same components. 4 key findings →
Design: RCT Participants: 2,111 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This long-term follow-up of the SPRINT randomized trial tested whether intensively lowering systolic blood pressure (to below 120, vs. the standard target of below 140) reduces the risk of thinking problems in adults 50+ with hypertension. 4 key findings →
Design: RCT Participants: 9,361 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →